SCHEMBL3280262

SCHEMBL3280262

CCOC(=O)c1cnc(OCC)cc1OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.49
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPC1 O15118 2/20 0.45
MAPT P10636 2/20 0.45
TSHR P16473 2/20 0.45
CYP3A4 P08684 1/20 0.45
HSP90AA1 P07900 1/20 0.44
KDM4E B2RXH2 3/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.43
THRB P10828 1/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20489593 0.83 DPP4 (0.48) DPP4ALDH1A1MEN1KMT2ANPC1
SCHEMBL31171418 0.81 TSHR (0.60) DPP4ALDH1A1MEN1KMT2AMAPT
SCHEMBL31171420 0.81 TSHR (0.60) DPP4ALDH1A1MEN1KMT2AMAPT
SCHEMBL1900744 0.80 DPP4 (0.46) DPP4ALDH1A1MEN1KMT2ANPC1
SCHEMBL17150208 0.75 DPP4 (0.47) DPP4ALDH1A1MEN1KMT2ATSHR
SCHEMBL1328058 0.75 MAPT (0.44) DPP4ALDH1A1NPC1MAPTTSHR
SCHEMBL4978958 0.74 DPP4 (0.40) DPP4MAPTKDM4E
SCHEMBL10394602 0.74 CA12 (0.49) DPP4ALDH1A1MEN1KMT2ANPC1
SCHEMBL1627964 0.74 DPP4 (0.57) DPP4MEN1KMT2AMAPTLMNA
SCHEMBL19502087 0.74 DPP4 (0.44) DPP4ALDH1A1NPC1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101370799-B Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors HOFFMANN LA ROCHE 2012-09-05 CN disclosed
US-7705007-B2 Cis-imidazolines HOFFMANN-LA ROCHE INC. (US) 2010-04-27 US disclosed
CN-101370799-A Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors HOFFMANN LA ROCHE (CH) 2009-02-18 CN disclosed
EP-1979338-A1 CIS-4, 5-BIARYL-2-HETEROCYCLIC-IMIDAZOLINES AS MDM2 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-10-15 EP disclosed
WO-2007082805-A1 CIS-4, 5-BIARYL-2-HETEROCYCLIC-IMIDAZOLINES AS MDM2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 WO disclosed
US-20070167437-A1 Cis-imidazolines FOTOUHI NADER 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167437-A1 Cis-imidazolines CCNI, CCNE1, CCNA1 DPP4 3616/4885ALDH1A1 613/4885MEN1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.